Literature DB >> 26278297

Primary Antiphospholipid Syndrome Associated with Diffuse Alveolar Hemorrhage and Pulmonary Thromboembolism.

Takuma Isshiki1, Keishi Sugino, Kyoko Gocho, Kenta Furuya, Hiroshige Shimizu, Muneyuki Sekiya, Takanori Ohata, Tomohiro Wada, Kazutoshi Isobe, Susumu Sakamoto, Yujiro Takai, Sakae Homma.   

Abstract

Antiphospholipid syndrome (APS) is clinically characterized by arterial or venous thrombosis; however, non-thromboembolic lung manifestations, such as diffuse alveolar hemorrhage (DAH), have also been previously reported. DAH is relatively common in APS patients with systemic lupus erythematosus, although it is rare in primary APS. We encountered a 78-year-old man who presented with hemoptysis and dyspnea. Chest CT showed diffuse ground-glass opacity with pulmonary thromboembolism. He was successfully treated with corticosteroids and heparin; however, DAH recurred after the corticosteroid treatment was stopped. The treatment was intricate due to the concurrent bleeding and thrombotic manifestations.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26278297     DOI: 10.2169/internalmedicine.54.4058

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Diffuse alveolar haemorrhage and Libman-Sacks endocarditis: a rare presentation of antiphospholipid syndrome.

Authors:  Brianna Bielski; Nikhil H Shah; Donevan Westerveld; Carolyn Stalvey
Journal:  BMJ Case Rep       Date:  2018-05-07

2.  Continous Rituximab treatment for recurrent diffuse alveolar hemorrhage in a patient with systemic lupus erythematosus and antiphosholipid syndrome.

Authors:  Signe Aakjær; Elisabeth Bendstrup; Per Ivarsen; Line Bille Madsen
Journal:  Respir Med Case Rep       Date:  2017-09-30

Review 3.  Clinical Insights into Diffuse Alveolar Hemorrhage in Antiphospholipid Syndrome.

Authors:  Sarah Abramson Stoots; Lindsay Lief; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2019-09-06       Impact factor: 4.592

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.